Lactokinin
Lactokinin is an Endothelin-1 (HY-P0202) release inhibitor and ACE inhibitor, with an ACE IC50 value of 29 μM. Lactokinin binds to bovine β-lactoglobulin variant A to form a non-covalent complex, which delays its hydrolysis by chymotrypsin, as well as by pepsin/chymotrypsin, in vitro. Lactokinin can be used in research related to hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 132160-04-4
- Formule: C37H64N12O8S
- Masse moléculaire:837.04
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
Lactokinin is bound to purified bovine β-lactoglobulin variant A via non-covalent interactions, and the bound peptide is protected from oxidation and ion adduction during ionization compared to free lactokinin[1].
Lactokinin (0.1-1 mM) inhibits basal and thrombin-stimulated endothelin-1 release from cultured porcine aortic endothelial cells, with 1 mM reducing basal release by 29% and 0.1 mM and 1 mM reducing thrombin-stimulated release by 32% and 43%, respectively[2].
Lactokinin inhibits porcine kidney angiotensin-converting enzyme activity with an IC50 of 29 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 132160-04-4
-
Masse moléculaire 837.04
-
Formule C37H64N12O8S
-
SMILES
C[C@H](N)C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CCSC)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)CC2=CN=CN2)=O)=O)=O)=O
-
Sequence
Ala-Leu-Pro-Met-His-Ile-Arg
-
Sequence Shortening
ALPMHIR
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
Références
[2]. Maes W, et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regulatory peptides. 2004 Apr 15;118(1-2):105-9. [Content Brief]
[3]. Pina AS, et al. Studies on the molecular recognition between bioactive peptides and angiotensin-converting enzyme. Journal of molecular recognition : JMR. 2009;22(2):162-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)